DK1104420T3 - Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer - Google Patents

Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer

Info

Publication number
DK1104420T3
DK1104420T3 DK99933078T DK99933078T DK1104420T3 DK 1104420 T3 DK1104420 T3 DK 1104420T3 DK 99933078 T DK99933078 T DK 99933078T DK 99933078 T DK99933078 T DK 99933078T DK 1104420 T3 DK1104420 T3 DK 1104420T3
Authority
DK
Denmark
Prior art keywords
naphthyridine
phosphodiesterase
inhibitors
ones
substituted
Prior art date
Application number
DK99933078T
Other languages
Danish (da)
English (en)
Inventor
Edward Fox Kleinman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1104420T3 publication Critical patent/DK1104420T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK99933078T 1998-08-11 1999-08-05 Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer DK1104420T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9617698P 1998-08-11 1998-08-11
PCT/IB1999/001390 WO2000009504A1 (en) 1998-08-11 1999-08-05 Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors

Publications (1)

Publication Number Publication Date
DK1104420T3 true DK1104420T3 (da) 2003-01-13

Family

ID=22256080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99933078T DK1104420T3 (da) 1998-08-11 1999-08-05 Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer

Country Status (44)

Country Link
US (1) US6174895B1 (pt)
EP (1) EP1104420B1 (pt)
JP (1) JP2002522541A (pt)
KR (1) KR20010072368A (pt)
CN (1) CN1312810A (pt)
AP (1) AP2001002068A0 (pt)
AR (1) AR015557A1 (pt)
AT (1) ATE229955T1 (pt)
AU (1) AU4924999A (pt)
BG (1) BG105321A (pt)
BR (1) BR9912902A (pt)
CA (1) CA2340180A1 (pt)
CO (1) CO5130004A1 (pt)
CZ (1) CZ2001485A3 (pt)
DE (1) DE69904602T2 (pt)
DK (1) DK1104420T3 (pt)
DZ (1) DZ2866A1 (pt)
EA (1) EA200100124A1 (pt)
EE (1) EE200100085A (pt)
ES (1) ES2188194T3 (pt)
GE (1) GEP20033029B (pt)
GT (1) GT199900128A (pt)
HK (1) HK1038917A1 (pt)
HN (1) HN1999000130A (pt)
HR (1) HRP20010107A2 (pt)
HU (1) HUP0103466A3 (pt)
ID (1) ID27843A (pt)
IL (1) IL140868A0 (pt)
IS (1) IS5815A (pt)
MA (1) MA26669A1 (pt)
NO (1) NO20010684L (pt)
NZ (1) NZ509297A (pt)
OA (1) OA11591A (pt)
PA (1) PA8480001A1 (pt)
PE (1) PE20000950A1 (pt)
PL (1) PL346005A1 (pt)
PT (1) PT1104420E (pt)
SK (1) SK1822001A3 (pt)
SV (1) SV1999000120A (pt)
TN (1) TNSN99155A1 (pt)
TR (1) TR200100433T2 (pt)
TW (1) TW542835B (pt)
WO (1) WO2000009504A1 (pt)
ZA (1) ZA200101040B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815951B2 (en) 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
JP2004532809A (ja) * 2000-11-02 2004-10-28 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
KR100454750B1 (ko) * 2002-06-20 2004-11-03 삼성에스디아이 주식회사 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자
JP2006508996A (ja) * 2002-11-27 2006-03-16 アルタナ　ファルマ　アクチエンゲゼルシャフト 悪液質の治療における使用のための、ｐｄｅ４及びｐｄｅ３／４インヒビター
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10349497A1 (de) * 2003-10-23 2005-05-25 Bayer Cropscience Ag N-substituierte Pyrazolylcarboxanilide
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
CA2552540A1 (en) * 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Use of substituted pteridines for the treatment of diseases of the respiratory tract
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
RS59921B1 (sr) * 2012-08-08 2020-03-31 Merck Patent Gmbh (aza-)izohinolinon derivati
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU165405B (pt) * 1972-06-29 1974-08-28
US3856800A (en) * 1973-02-26 1974-12-24 Sterling Drug Inc Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates
US3882132A (en) * 1973-03-08 1975-05-06 Sterling Drug Inc Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs
AU3265695A (en) * 1994-08-29 1996-03-22 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤

Also Published As

Publication number Publication date
TR200100433T2 (tr) 2001-07-23
ID27843A (id) 2001-04-26
HUP0103466A3 (en) 2002-11-28
BR9912902A (pt) 2001-05-08
DE69904602T2 (de) 2003-04-30
PL346005A1 (en) 2002-01-14
EE200100085A (et) 2002-08-15
CZ2001485A3 (cs) 2002-05-15
GT199900128A (es) 2001-01-30
TW542835B (en) 2003-07-21
HN1999000130A (es) 2000-11-22
GEP20033029B (en) 2003-07-25
AP2001002068A0 (en) 2001-03-31
PE20000950A1 (es) 2000-09-27
NZ509297A (en) 2003-11-28
ZA200101040B (en) 2003-01-07
IS5815A (is) 2001-01-16
ATE229955T1 (de) 2003-01-15
HUP0103466A2 (hu) 2002-02-28
PT1104420E (pt) 2003-03-31
SV1999000120A (es) 2000-09-05
DZ2866A1 (fr) 2003-12-01
HRP20010107A2 (en) 2002-02-28
ES2188194T3 (es) 2003-06-16
IL140868A0 (en) 2002-02-10
EP1104420B1 (en) 2002-12-18
KR20010072368A (ko) 2001-07-31
HK1038917A1 (zh) 2002-04-04
MA26669A1 (fr) 2004-12-20
WO2000009504A1 (en) 2000-02-24
EA200100124A1 (ru) 2001-10-22
US6174895B1 (en) 2001-01-16
DE69904602D1 (en) 2003-01-30
BG105321A (en) 2001-12-29
AR015557A1 (es) 2001-05-02
PA8480001A1 (es) 2000-09-29
CA2340180A1 (en) 2000-02-24
CO5130004A1 (es) 2002-02-27
AU4924999A (en) 2000-03-06
OA11591A (en) 2004-07-30
SK1822001A3 (en) 2002-08-06
NO20010684D0 (no) 2001-02-09
NO20010684L (no) 2001-04-09
JP2002522541A (ja) 2002-07-23
CN1312810A (zh) 2001-09-12
TNSN99155A1 (fr) 2005-11-10
EP1104420A1 (en) 2001-06-06

Similar Documents

Publication Publication Date Title
DK1104420T3 (da) Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer
DK1114032T3 (da) 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
NO20011350D0 (no) 4-Karboksyaminosubstituerte 1,2,3,4-tetrahydrokinoliner som CETP inhibitorer
LU93311I2 (fr) Mancozèbe, valifenalate
DK1114033T3 (da) 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1140935T3 (da) 1,2-anellerede quinolinderivater
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
IS6024A (is) Ný efnasambönd
EE200200033A (et) Uued ühendid
EE200000717A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat III
DZ3244A1 (fr) Inhibiteurs de 8-arylquinoline phosphodiesterase-4 substituee
PT1171440E (pt) 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
ATE387448T1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
NO20032807D0 (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
DK1254118T3 (da) Substituerede 1,2,3,4-tetrahudroquinolin-2-carboxylsyrederivater
ATE317396T1 (de) 14,15-beta-methylen substituierte androgene
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
DE59909590D1 (de) Azidfreie, gaserzeugende zusammensetzung
ATE264308T1 (de) Aminoalkyl-3,4-dihydrochinolin-derivate als no synthase inhibitoren
ATE470655T1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen